RC48, a novel HER2-targeting ADC, has exhibited remarkable clinical efficacy across trials, demonstrating substantial antitumor activity even in the challenging population of HER2-low advanced breast cancer [13,19,20]. This evidence concerns the gene ERBB2 and breast cancer.